Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq: IDYA) on Monday announced the successful completion of a Type D meeting with the U.S. Food and Drug Administration regarding the design of its Phase 3 registrational trial for darovasertib as a neoadjuvant therapy in primary uveal melanoma (UM).
Targeting a launch in H1 2025, the trial will enrol approximately 520 patients across two cohorts: 120 enucleation-eligible patients and 400 plaque brachytherapy (PB)-eligible patients, randomised 2:1 to receive darovasertib or control. The study will assess darovasertib's ability to preserve vision and prevent eye removal prior to conventional treatment.
Eye preservation rate will serve as the primary endpoint for the enucleation cohort, while loss of visual acuity post-treatment will be the key measure for the PB cohort. A secondary endpoint of no detriment to event-free survival (EFS) is required for approval. IDEAYA may seek regulatory review for the enucleation data ahead of the PB cohort, pending EFS data maturity.
Darovasertib, a selective PKC inhibitor, holds FDA Breakthrough Therapy Designation in neoadjuvant primary UM and Fast Track designation in combination with crizotinib for metastatic UM. It is also designated as an Orphan Drug for UM.
IDEAYA's precision medicine approach integrates molecular diagnostics and biomarker-driven patient selection, with an emphasis on synthetic lethality targets.
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
MHRA to review monthly maintenance dosing for Leqembi in early Alzheimer's treatment
Ro integrates with NovoCare Pharmacy to offer access to all doses of Wegovy at lowest price
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy